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Abstract Flow cytometry was used to demonstrate that
cultured human melanoma BRO cells expressed membrane-
bound tumour necrosis factor-alpha (TNF-K) and were able to
release TNF-K upon treatment with glucosaminylmuramyl
dipeptide (GMDP). The released TNF-K was shown to prime
melanoma cells, previously unable to respond to GMDP by
increasing expression of melanoma-associated antigens, making
them sensitive to GMDP treatment.
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1. Introduction
Glucosaminylmuramyl dipeptide (GMDP) is known as po-
tent immunomodulator which can cause inhibition of growth
and necrosis of certain experimental tumours in mice [1]. We
have reported earlier that the mechanism of GMDP anti-tu-
mour activity, besides the activation of immune cells, involved
induction of expression of tumour-associated antigens
(TAAs), ICAM-1 and other antigens on tumour cells, in par-
ticular on human melanoma BRO [2^4]. The changes in the
phenotype of melanoma BRO cells resulted in their increased
lysis by peripheral blood cells of healthy donors [4]. Only a
fraction of melanoma cells was able to respond to GMDP by
increasing expression of melanoma-associated antigens, but
the number of responding cells and the magnitude of the
response increased considerably upon additional introduction
of GMDP after 24 h of in vitro cultivation with this muramyl
peptide [4,5]. In the present study we investigated the mecha-
nism of this e¡ect and have shown that TNF-K produced by
melanoma cells was the priming agent.
2. Materials and methods
2.1. Antibodies and reagents
Monoclonal antibody (mAb) MCA-C1 (ATCC HB 8443) against
melanoma-associated antigen (MAA) was kindly provided by Dr. E.S.
Revazova (All-Russia Oncological Centre, Moscow), mAb 5A899
binding human IL-1L, by Dr. V.L. Yurin (State Research Centre
‘Genetics’, Moscow), and mAb E7H2 against human TNF-K [6], by
O.G. Shamborant (Shemyakin-Ovchinnikov Institute of Bioorganic
Chemistry, Moscow). mAb reactive with TGF-L1L2L3 was purchased
from Pharmingen, USA (Cat. No. 1835-01). rTNF-K was a gift of Dr.
V.G. Korobko (Shemyakin-Ovchinnikov Institute of Bioorganic
Chemistry, Moscow). rTNF-K had speci¢c activity 1^2U107 U/mg
protein. It was more than 95% pure and contained less than 2 ng/
mg TNF-K of endotoxin [7]. GMDP was synthesised as described in
[8].
2.2. Cell culture
BRO and A-549 cells were cultivated as had been described in [4] in
the mixture of Dulbecco’s MEM/F12 Ham’s medium (1:1), containing
10% foetal calf serum (FCS), 10 Wg/ml gentamycin and 10 mM
HEPES (complete medium). In several experiments cells were culti-
vated in serum-free DMEM/F12 Ham’s medium, supplemented only
with 10 mM HEPES.
2.3. Treatment with muramyl peptides
GMDP or MDP in water (10 Wl) was added to 2U105 melanoma
BRO or lung adenocarcinoma A-549 cells in 1 ml of complete or
serum-free medium in 24-well plates. Incubation was carried out at
37‡C. In control cultures water was substituted for muramyl peptide
solution. When necessary second portion of muramyl peptide was
added at 24 h. MCA-C1 expression was evaluated at 24 h after the
second addition of muramyl peptide.
2.4. Trypsin digestion
Culture supernatant obtained by stimulation of BRO cells in serum-
free medium was dialysed against phosphate-bu¡ered saline (PBS),
pH 7.4, for 18 h with one change of bu¡er. Trypsin in PBS was added
to make ¢nal concentration 75 Wg/ml, and the incubation was carried
out for 4 h at 37‡C. The sample was dialysed against incomplete
medium. FCS was added (20 Wl/ml) and TNF-K activity was evaluated
by bioassay.
2.5. Heat inactivation
Culture supernatant was heated in boiling water bath for 1 min and
dialysed against incomplete culture medium. FCS (20 Wl/ml) was
added, and the bioassay was performed.
2.6. Cytokine neutralisation assay
Anti-TGF-L1L2L3 (30 Wg/ml), anti-IL-1L (100 Wg/ml) and anti-
TNF-K (80 Wg/ml) mAbs were dissolved in PBS, pH 7.4. Serial dilu-
tions of mAbs (1:5, 1:10, 1:20, 20 Wl) were added to melanoma cell
cultures (2U105 cells in 1 ml of complete medium) pre-treated for 24 h
with GMDP (0.1 Wg/ml). No mAb was added to control culture.
GMDP (20 Wg/ml) was added after 1 h incubation, and the incubation
was continued for another 24 h. The percentage of MCA-C1 positive
cells was evaluated by £ow cytometry. The inhibition was calculated
as follows:
2.7. TNF-K bioassay
TNF-K bioassay was performed using TNF-sensitive L929 cells.
Cytotoxicity was assessed by MTT test as in [9]. L929 cells in
RPMI 1640 medium, containing 10% FCS and 0.5 Wg/ml Actinomycin
D (Sigma, USA), were placed into wells of 96-well microtitre plate
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(4U104 cells in 180 Wl medium per well). Twenty Wl of rTNF-K (0.1^
200 U/well) in complete medium or serial dilutions (1:10, 1:100,
1:1000) of dialysed supernatant from muramyl peptide treated BRO
cells were added. The culture supernatant was dialysed against incom-
plete medium for 18 h with one change of medium and reconstituted
before the assay with FCS to make 10% (v/v) ¢nal concentration.
Incubation was carried out for 18 h at 37‡C. MTT solution (0.5%,
10 Wl) in PBS, pH 7.3, was added, and the incubation was continued
for another 4 h. Supernatants were removed from wells, and cells were
treated with 100 Wl of 0.04 N HCl in isopropyl alcohol to dissolve
formazan crystals. Optical density at 540 nm was assessed after 15
min incubation. Statistical analysis was carried out by Student’s test
using Statgraft program.
2.8. Flow cytometry
Staining of cells with FITC-labelled antibodies was performed as
described by Valyakina et al. [2]. Brie£y, cells were removed from the
wells of 24-well plate with the aid of cell scraper, washed three times
with PBS, pH 7.4, containing 2% FCS (PBS-FCS), and incubated for
30 min at 4‡C with 100 Wl of corresponding mAb solution in PBS-
FCS, containing 10 Wg mAb. After two washes with cold PBS-FCS,
cells were treated for 30 min with FITC-labelled rabbit anti-mouse
immunoglobulin antibodies (DAKO, Denmark, 1/100 dilution). Cells
were washed 3 times with PBS-FCS, suspended in 1 ml PBS and
analysed using EPICS-V £ow cytometer, equipped with Spectra
Physics laser (excitation wavelength 488 nm, power output 200 mV,
barrier ¢lter 515 nm). In each experiment at least ten thousand cells
were analysed. Calculations were made with the aid of the MDADS
software (Coultronics, France).
3. Results
In the previous study we have observed that treatment of
tumour cells with GMDP resulted in initial (at 6 h) drop in
the number of tumour-associated antigen expressing cells and
the mean density of TAAs on cell surface followed by increase
in these parameters with maximum at 24^48 h [2]. When the
second portion of GMDP was added after 24 h the magnitude
of the response increased considerably. In the case of mela-
noma BRO at optimal GMDP concentration the number of
melanoma-associated antigen (MCA-C1 and MUC-18) ex-
pressing cells increased from 28% MCA-C1 and 13% MUC-
18 positive cells to 45% and 29% respectively. Upon primary
GMDP treatment the dose-response relationship had typical
for immunomodulators bell-like shape. The MCA-C1 and
MUC-18 antigen expression peaked at 0.1 Wg/ml muramyl
peptide concentration. The study of the dose-response rela-
tionship to second GMDP introduction revealed that substan-
tially higher GMDP concentration (20 Wg/ml) was required
for optimal response (Fig. 1).
The e¡ect of GMDP priming on melanoma cells previously
non-responding to muramyl peptide action was completely
abrogated by change of culture supernatant for a fresh me-
dium before second addition of GMDP. Moreover, addition
of this supernatant to fresh melanoma cells along with opti-
mum dose (20 Wg/ml) of GMDP resulted in MCA-C1 expres-
sion characteristic for secondary GMDP response. It was
noteworthy that melanoma cells had to be incubated with
GMDP for at least 24 h before their conditioned medium
acquired potency to prime intact cells.
The above results enabled us to assume the presence of cell
priming factor in the conditioned medium of GMDP treated
melanoma cells. The released factor was non-speci¢c: the fac-
tor produced by melanoma cells was capable of priming lung
adenocarcinoma A-549 cells and vice versa. In order to char-
acterise this factor we performed GMDP stimulation in se-
rum-free medium followed by trypsin treatment of superna-
tant. The loss of factor activity upon this treatment proved it
to be a protein. The loss of factor activity was observed also
upon heating. In contrast freezing-thawing resulted in consid-
erable enhancement of factor activity. Evidently this could be
due to dissociation of oligomeric factor molecules.
To identify GMDP priming factor we tried to neutralise the
activity with monoclonal antibodies to known cytokines,
namely TGF-L, IL-1L and TNF-K. Only mAb to TNF-K
was able to completely inhibit priming activity of conditioned
medium assuming that this cytokine was responsible for the
e¡ect (Fig. 2).
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Fig. 1. Expression of MCA-C1 antigen on melanoma BRO cells cul-
tivated in vitro with GMDP. A: Non-treated cells (control); B: sin-
gle addition of GMDP (0.1 Wg); C^G: double addition of GMDP
with 24 h interval. First addition: 0.1 Wg; second addition: C, 0.1
Wg; D, 1 Wg; E, 10 Wg; F, 20 Wg; G, 50 Wg. MCA-C1 positive cells
were counted using £ow cytometry after £uorescent labelling with
corresponding mAb 24 h after the last addition of GMDP. The
data present the mean values of at least three separate analyses.
S.D. does not exceed 10%.
Fig. 2. Neutralisation of priming activity of supernatant of GMDP
treated BRO cells with mAb against TNF-K, IL-1L and TGF-L. Se-
rial dilutions of mAbs were added to melanoma cell cultures pre-
treated for 24 h with GMDP (0.1 Wg/ml). GMDP (20 Wg/ml) was
added after 1 h incubation with mAb, and the incubation was con-
tinued for another 24 h. The percentage of MCA-C1 positive cells
was evaluated by £ow cytometry. Inhibition was calculated as de-
scribed in Section 2.
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The presence of TNF-K in the condition medium from
GMDP-induced melanoma cells was con¢rmed by biological
test. Culture supernatant from growing melanoma cells was
not cytotoxic to TNF-sensitive L929 murine ¢broblasts
whereas after 24 h GMDP stimulation the killing of L929
cells by the conditioned medium was observed (Fig. 3).
GMDP remaining in supernatant (if any) could not by any
means contribute to L929 killing, because it was removed by
dialysis before the assay.
To prove the ability of TNF-K to sensitise BRO cells to
GMDP treatment we used recombinant cytokine which was
added to melanoma cell culture along with GMDP dose opti-
mal for secondary response. Twenty-four h later MCA-C1
expression was evaluated. As can be seen from Fig. 4 recombi-
nant TNF-K (100 U/ml) completely reproduced the e¡ect of
GMDP priming. The same result was obtained when TNF-K
was added 2 h before the introduction of GMDP.
Flow cytometry was used to characterise the expression of
TNF-K by BRO cells. Initially about 30% of cells had TNF-K
on plasma membrane (Fig. 5). Treatment of cells with GMDP
resulted in the release of TNF-K, and after 24 h incubation the
cytokine could not be detected on cell surface. Evidently
GMDP increased biosynthesis of TNF-K and induced its re-
lease from BRO cells.
In contrast to GMDP another well studied muramyl pep-
tide, MDP, over wide concentration range (0.1^50 Wg/ml) was
not able to a¡ect expression of MCA-C1 antigen and TNF-K
on melanoma cells (data not shown), though it was known to
induce TNF-K biosynthesis by macrophages [10]. When intro-
duced together with TNF-K MDP was not able to augment
MCA-C1 expression. Noteworthy MDP unlike GMDP was
not capable of causing necrosis of experimental tumours [11].
4. Discussion
The results presented above demonstrate that stimulation of
melanoma BRO cells with GMDP results in accumulation of
TNF-K in condition medium. The production of this cytokine
is not unique for melanoma BRO. Sander and Boeryd [12]
have found that 12 out of 17 primary melanomas expressed
TNF-K. It was found as well in other transformed cells where
it performed the role of autocrine or paracrine growth factor
[13,14]. The correlation of the TNF-K expression and meta-
static potential of cancer cells was reported [15^17], namely,
tumour cell-associated TNF-K induced expression of ICAM-1
and VCAM on vascular endothelium cells, facilitating high-
a⁄nity binding of tumour cells via L2-integrins and leading to
tumour cell invasion.
In our hands TNF-K accumulating in culture medium was
not cytotoxic to melanoma cells, but primed previously non-
responding melanoma cells to subsequent GMDP treatment.
The priming e¡ect of conditioned medium from GMDP-
stimulated lung adenocarcinoma cells on melanoma BRO
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Fig. 5. Expression of TNF-K by melanoma BRO cells treated with
GMDP (0.1 Wg/ml) for 0^24 h. The percentage of TNF-K positive
cells was evaluated by £ow cytometry. The data present the mean
values of at least three separate analyses. S.D. does not exceed 10%.
Fig. 4. Priming by rTNF-K of melanoma BRO cells to GMDP
treatment. Cells were incubated for 24 h; A: without stimulators
(control); B: with GMDP (20 Wg/ml) alone; C^G: with (black bars)
or without (white bars) GMDP (20 Wg/ml) and various doses of
TNF-K. C, 10 U/ml; D, 50 U/ml; E, 100 U/ml; F, 200 U/ml; G,
500 U/ml.
Fig. 3. Cytotoxic e¡ect of culture supernatant from GMDP-induced
melanoma BRO cells on murine L929 cells. a: Supernatant from
cultured BRO cells (control); b: supernatant from GMDP-induced
BRO cells; c : recombinant TNF-K. Cytotoxicity was evaluated us-
ing MTT test [9].
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demonstrated that cytokine priming was not a unique feature
of melanoma cells. That TNF-K was responsible for this e¡ect
was proved by neutralisation of supernatant priming activity
with anti-TNF-K mAb as well as by priming of melanoma
cells by rTNF-K.
The mechanism of TNF-K priming probably involved the
exposure of new GMDP-binding sites by tumour cells. Vari-
ous cytokines including TNF-K are known to induce expres-
sion of cell surface molecules [16]. Previously we demonstrated
the presence of GMDP-binding sites inside BRO cells though
the presence of low number of surface GMDP receptors was
not ruled out (non-published results). The increase in number
of membrane-binding sites on murine macrophages for anoth-
er muramyl peptide, namely, MDP-stearoyl-lysine on murine
macrophages upon cytokine priming was reported earlier for
Ifn-Q [18]. The high dose of GMDP required for secondary
GMDP response might re£ect the lower a⁄nity of newly ex-
pressed binding sites on induced BRO cells. The alteration of
the a⁄nity of MDP-binding sites upon cell activation was
reported earlier by Silverman et al. for murine macrophages
[19].
Not only GMDP, but other muramyl peptides as well are
known to co-operate with TNF-K. The enhancement of IL-6
gene expression was observed upon simultaneous introduction
of MDP and TNF-K into human monocytes culture [20]. Co-
operative e¡ect was also characteristic for these compounds in
the induction of host resistance to bacterial infections [21].
Hence, taking in account that muramyl peptides induce
TNF-K biosynthesis, the data obtained thus far points out
that TNF-K might be involved in various activities of mur-
amyl peptides, in particular, in anti-tumour activity of GMDP
and, possibly, of other muramyl peptides. These immunomod-
ulators seem to synergise activating immune cells and modify
the phenotype of tumour cells. Besides, the priming e¡ect of
TNF-K on tumour cells might explain the earlier established
fact that GMDP caused necrosis of only well developed tu-
mours [8]. The reason for this was not established, but evi-
dently only at the late stage of tumour development enough
TNF-K is released for tumour cell priming.
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